

Basel, 10 November 2008



**Speedel Holding Ltd**  
Hirschgässlein 11  
CH - 4051 Basel  
Switzerland

**Dr. Andrin Oswald**  
CEO

T +41 (0) 61 206 40 00  
D +41 (0) 61 206 40 10  
F +41 (0) 61 206 40 01  
E [andrin.oswald@speedel.com](mailto:andrin.oswald@speedel.com)  
[www.speedel.com](http://www.speedel.com)

Dear Business Partner,

We are entering the final phase of the integration of Speedel into Novartis.

After a successful public tender offer Novartis now owns approximately 99.8% of Speedel's stock. The "squeeze-out" procedure has been initiated and shall be finalized early 2009. However, operational integration is near to completion. As a result of these actions there are a number of changes that, as partners, we wish to alert to you:

- Speedel projects are currently being transferred to Novartis Cardiovascular and Metabolism (CVM) Business Franchise as well as Novartis Institute for Biomedical Research (NIBR). We expect this process to be finalized by mid-November.
- Speedel's offices will close shortly after all integration processes are finalized, currently foreseen by end 2008.
- For invoicing purposes the old Speedel address may still be used as post will be diverted to the managers of continuing projects.
- As of today, the Speedel website [www.speedel.com](http://www.speedel.com) has been updated with Novartis contact information to facilitate future communications

In closing, I would like to take this opportunity to thank you for supporting Speedel over the past years. For Novartis, cardiovascular medicines remain a focus for future development efforts to improve patient treatment. Together we aim to continue the successful development of new medicines in this area.

Should you have any questions related to the above, please see attached contact sheet or feel free to reach out to me directly.

Best wishes and kind regards,

**Dr. Andrin Oswald**  
**CEO Speedel**

## **Business Contacts within Novartis**

### **Novartis Pharma**

Global Head CVM Development Franchise  
(Development)

Ameet Nathwani  
[ameet.nathwani@novartis.com](mailto:ameet.nathwani@novartis.com)

Global Head CVM Business Franchise  
(Global Marketing & Sales)

John Glasspool  
[john.glasspool@novartis.com](mailto:john.glasspool@novartis.com)

### **Novartis Institutes for BioMedical Research (NIBR)**

Head of Disease Area Neuroscience Research  
(Research and Development)

Graeme Bilbe  
[graeme.bilbe@novartis.com](mailto:graeme.bilbe@novartis.com)

### **Investor Relations/ Media Relations**

Manager Investor Relations

Thomas Hungerbühler, Investor Relations  
[thomas.hungerbuehler@novartis.com](mailto:thomas.hungerbuehler@novartis.com)

Director Global Media Relations

Eric Althoff  
[eric.althoff@novartis.com](mailto:eric.althoff@novartis.com)

### **Others**

Finance

Norbert Staub  
[norbert.staub@novartis.com](mailto:norbert.staub@novartis.com)

Facilities

Patrick Burgherr  
[patrick.burgherr@novartis.com](mailto:patrick.burgherr@novartis.com)